Literature DB >> 22965952

Targeting mutant p53 in human tumors.

Brian D Lehmann1, Jennifer A Pietenpol.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965952     DOI: 10.1200/JCO.2012.44.0412

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  37 in total

1.  Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.

Authors:  Wei Zhang; Bin Yi; Chao Wang; Dongquan Chen; Sejong Bae; Shi Wei; Rong-Jun Guo; Changming Lu; Lisa L H Nguyen; Wei-Hsiung Yang; James W Lillard; Xingyi Zhang; Lizhong Wang; Runhua Liu
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

2.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

3.  CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo.

Authors:  Xingxing He; Xinjuan Kong; Junwei Yan; Jingjun Yan; Yunan Zhang; Qian Wu; Ying Chang; Haitao Shang; Qian Dou; Yuhu Song; Fang Liu
Journal:  Tumour Biol       Date:  2015-02-08

Review 4.  Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.

Authors:  Ammad Ahmad Farooqi; Zahid H Siddik
Journal:  Cell Biochem Funct       Date:  2015-07-07       Impact factor: 3.685

5.  EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.

Authors:  Yu Zhao; Liya Ding; Dejie Wang; Zhenqing Ye; Yundong He; Linlin Ma; Runzhi Zhu; Yunqian Pan; Qiang Wu; Kun Pang; Xiaonan Hou; Saravut J Weroha; Conghui Han; Roger Coleman; Ilsa Coleman; R Jeffery Karnes; Jun Zhang; Peter S Nelson; Liguo Wang; Haojie Huang
Journal:  EMBO J       Date:  2019-02-05       Impact factor: 11.598

6.  Poor survival with wild-type TP53 ovarian cancer?

Authors:  Kwong-Kwok Wong; Daisy I Izaguirre; Suet-Yan Kwan; Erin R King; Michael T Deavers; Anil K Sood; Samuel C Mok; David M Gershenson
Journal:  Gynecol Oncol       Date:  2013-06-22       Impact factor: 5.482

Review 7.  Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.

Authors:  Brian D Lehmann; Jennifer A Pietenpol
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

8.  The effects of cell compressibility, motility and contact inhibition on the growth of tumor cell clusters using the Cellular Potts Model.

Authors:  Jonathan F Li; John Lowengrub
Journal:  J Theor Biol       Date:  2013-11-06       Impact factor: 2.691

9.  CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.

Authors:  Xing-Xing He; Yu-Nan Zhang; Jun-Wei Yan; Jing-Jun Yan; Qian Wu; Yu-Hu Song
Journal:  Tumour Biol       Date:  2015-08-07

Review 10.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.